Observational studyClinical cancer research : an official journal of the American Association for Cancer Research2018
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
Open access · greenAbstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 4 pooled it
21.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 4 syntheses or guidelines pooled it, 215 citations in OpenAlex.
- Comparison of the efficacy based on clinicopathological characteristics and the safety of first-line treatments for patients with advanced ALK rearrangement non-small cell lung cancer: a network meta-analysis.Frontiers in oncology · 2025Pooled it
- Non-small cell lung cancer withFrontiers in oncology · 2023Pooled it
- Impact of Smoking on Response to the First-Line Treatment of Advanced ALK-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.Frontiers in pharmacology · 2022Pooled it
- Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.BMC cancer · 2020Pooled it
- Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.Genome medicine · 2021Trial
- Association of TP53 gain-of-function mutations with early osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma.ESMO open · 2026Article
- High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors.Clinical lung cancer · 2026Article
- A Prognostic Signature for Lung Adenocarcinoma in Patients Who Have Never Smoked.Cancer discovery · 2026Article
- Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLC.Frontiers in oncology · 2026Article
- Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026Review
- Evolving roles of MET as a therapeutic target in NSCLC and beyond.Nature reviews. Clinical oncology · 2025Review
- A prognostic signature for lung adenocarcinoma in people who have never smoked.bioRxiv : the preprint server for biology · 2025Article
- Deciphering bidirectional causal links between oxidative stress and lung cancer risk through Mendelian randomization.Discover oncology · 2025Article
- Afatinib and Necitumumab inJTO clinical and research reports · 2025Article
- Effects of Tp53 Gene Mutations on the Survival of Non-Small Cell Lung Cancer (NSCLC); A Short Review.Cancer management and research · 2025Review
- Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements.Therapeutic advances in medical oncology · 2025Article
- Radiomics for differentiating adenocarcinoma and squamous cell carcinoma in non-small cell lung cancer beyond nodule morphology in chest CT.Scientific reports · 2024Article
- Long-Term Outcomes in Patients with EGFR Positive Lung Adenocarcinoma and Subgroup Analysis Based on Presence of Liver Metastases.Current issues in molecular biology · 2024Article
- Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC.JTO clinical and research reports · 2024Article
- Is there a prognostic difference among stage I lung adenocarcinoma patients with different BRAF-mutation status?Thoracic cancer · 2024Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
28 authors at 4 institutions in 1 country.
Dara L Aisner *University of Colorado Cancer Center, Aurora, Colorado. dk@rics.bwh.harvard.edu dara.aisner@ucdenver.edu.
Lynette M Sholl *Brigham and Women's Hospital, Boston, Massachusetts.
Lynne D Berry *Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Michael R Rossi *Winship Cancer Institute of Emory University, Atlanta, Georgia.
Heidi ChenVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Junya FujimotoThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Andre L MoreiraMemorial Sloan Kettering Cancer Center, New York, New York.
Suresh S RamalingamWinship Cancer Institute of Emory University, Atlanta, Georgia.
Liza C VillaruzUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
Gregory A OttersonOhio State Comprehensive Cancer Center, Columbus, Ohio.
Eric HauraH. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Katerina PolitiYale University Medical Center, New Haven, Connecticut.
Bonnie GlissonThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Jeremy CetnarOregon Health Sciences University, Portland, Oregon.
Edward B GaronDavid Geffen School of Medicine, University of California, Los Angeles, California.
Joan SchillerUniversity of Texas Southwestern, Medical Center, Dallas, Texas.
Saiama N WaqarWashington University School of Medicine, St. Louis, Missouri.
Lecia V SequistMassachusetts General Hospital, Boston, Masschusetts.
Julie BrahmerThe Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Yu ShyrVanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Kelly KuglerUniversity of Colorado Cancer Center, Aurora, Colorado.
Ignacio I WistubaThe University of Texas MD Anderson Cancer Center, Houston, Texas.
Bruce E JohnsonDana-Farber Cancer Institute, Boston, Massachusetts.
John D MinnaUniversity of Texas Southwestern, Medical Center, Dallas, Texas.
Mark G KrisMemorial Sloan Kettering Cancer Center, New York, New York.
Paul A BunnUniversity of Colorado Cancer Center, Aurora, Colorado.
David J KwiatkowskiBrigham and Women's Hospital, Boston, Massachusetts. dk@rics.bwh.harvard.edu dara.aisner@ucdenver.edu.
LCMC2 investigators
Dana-Farber Cancer Institute · USThe University of Texas MD Anderson Cancer Center · USKettering University · USMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MUniversity of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MTuberous Sclerosis-Pathway and PathogenesisP01CA120964 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI David J. Kwiatkowski · 2007 to 2026
$35.9MA model for predicting response to PD-1 inhibitors in NSCLCR01CA208403 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GARON, EDWARD B · 2017 to 2021
$3.2MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA208403
Abstract
PubMed holds no abstract for this paper.
Indexed as
Adenocarcinoma of LungAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorCarcinogenesisDNA Mutational AnalysisFemaleHigh-Throughput Nucleotide SequencingHumansLung NeoplasmsMaleMiddle AgedMolecular Targeted TherapyMutationAntineoplastic AgentsBiomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.